{"id":"https://openalex.org/W3213811745","doi":"https://doi.org/10.1182/blood-2021-152126","title":"A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma","display_name":"A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma","publication_year":2021,"publication_date":"2021-11-05","ids":{"openalex":"https://openalex.org/W3213811745","doi":"https://doi.org/10.1182/blood-2021-152126","mag":"3213811745"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2021-152126","doi":"https://doi.org/10.1182/blood-2021-152126","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-152126","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036697187","display_name":"Kirk E. Cahill","orcid":"https://orcid.org/0000-0002-1313-4943","observed_orcids":["https://orcid.org/0000-0002-1313-4943"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]},{"id":"https://openalex.org/I4390039251","display_name":"University of Chicago Medicine Comprehensive Cancer Center","ror":"https://ror.org/042wftp98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865","https://openalex.org/I4390039251"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kirk Cahill","raw_affiliation_strings":["Comprehensive Cancer Center, University of Chicago Medicine, Chicago, IL","Section of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Comprehensive Cancer Center, University of Chicago Medicine, Chicago, IL","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4390039251"]},{"raw_affiliation_string":"Section of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077646722","display_name":"Michael J. Leukam","orcid":"https://orcid.org/0000-0002-7342-6649","observed_orcids":["https://orcid.org/0000-0002-7342-6649"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Leukam","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Boston, MA","Department of Medicine, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Boston, MA","institution_ids":["https://openalex.org/I1316535847"]},{"raw_affiliation_string":"Department of Medicine, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038171309","display_name":"Theodore G Karrison","orcid":"https://orcid.org/0009-0009-8641-5111","observed_orcids":["https://orcid.org/0009-0009-8641-5111"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4390039251","display_name":"University of Chicago Medicine Comprehensive Cancer Center","ror":"https://ror.org/042wftp98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865","https://openalex.org/I4390039251"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Theodore G. Karrison","raw_affiliation_strings":["Comprehensive Cancer Center, University of Chicago Medicine, Chicago, IL","Department of Public Health Sciences, University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Comprehensive Cancer Center, University of Chicago Medicine, Chicago, IL","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4390039251"]},{"raw_affiliation_string":"Department of Public Health Sciences, University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042206492","display_name":"Jessica A. Robertson","orcid":"https://orcid.org/0000-0001-6458-7347","observed_orcids":["https://orcid.org/0000-0001-6458-7347"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica Robertson","raw_affiliation_strings":["Section of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008824892","display_name":"Justin Paul Kline","orcid":"https://orcid.org/0000-0002-2967-6448","observed_orcids":["https://orcid.org/0000-0002-2967-6448"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4390039251","display_name":"University of Chicago Medicine Comprehensive Cancer Center","ror":"https://ror.org/042wftp98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865","https://openalex.org/I4390039251"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Justin Kline","raw_affiliation_strings":["Comprehensive Cancer Center, University of Chicago Medicine, Chicago, IL","Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Comprehensive Cancer Center, University of Chicago Medicine, Chicago, IL","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4390039251"]},{"raw_affiliation_string":"Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005159945","display_name":"Sonali M. Smith","orcid":"https://orcid.org/0000-0002-9893-4949","observed_orcids":["https://orcid.org/0000-0002-9893-4949"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4390039251","display_name":"University of Chicago Medicine Comprehensive Cancer Center","ror":"https://ror.org/042wftp98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865","https://openalex.org/I4390039251"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sonali M. Smith","raw_affiliation_strings":["Comprehensive Cancer Center, University of Chicago Medicine, Chicago, IL","Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Comprehensive Cancer Center, University of Chicago Medicine, Chicago, IL","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4390039251"]},{"raw_affiliation_string":"Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"138","issue":"Supplement 1","first_page":"2420","last_page":"2420"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.8657000064849854,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.8657000064849854,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.13040000200271606,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/follicular-lymphoma","display_name":"follicular lymphoma","score":0.9330000281333923},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.996999979019165},{"id":"https://openalex.org/keywords/obinutuzumab","display_name":"obinutuzumab","score":0.8960000276565552},{"id":"https://openalex.org/keywords/cc-486","display_name":"CC-486","score":0.8529999852180481},{"id":"https://openalex.org/keywords/bcl-2-inhibition","display_name":"BCL-2 inhibition","score":0.9039999842643738},{"id":"https://openalex.org/keywords/mcl-1","display_name":"Mcl-1","score":0.8379999995231628},{"id":"https://openalex.org/keywords/epigenetic-modulation","display_name":"epigenetic modulation","score":0.7590000033378601},{"id":"https://openalex.org/keywords/dna-methylation","display_name":"DNA methylation","score":0.7710000276565552},{"id":"https://openalex.org/keywords/anti-cd20-therapy","display_name":"anti-CD20 therapy","score":0.871999979019165},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6330000162124634},{"id":"https://openalex.org/keywords/frontline-treatment","display_name":"frontline treatment","score":0.6890000104904175},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.4519999921321869},{"id":"https://openalex.org/keywords/bcl2-rearrangement","display_name":"BCL2 rearrangement","score":0.6589999794960022}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.9467535018920898},{"id":"https://openalex.org/C2777607594","wikidata":"https://www.wikidata.org/wiki/Q389496","display_name":"Obinutuzumab","level":4,"score":0.6173155307769775},{"id":"https://openalex.org/C2777058707","wikidata":"https://www.wikidata.org/wiki/Q123251","display_name":"Follicular lymphoma","level":3,"score":0.6019414067268372},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.574341356754303},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5187092423439026},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4660310447216034},{"id":"https://openalex.org/C41091548","wikidata":"https://www.wikidata.org/wiki/Q26939","display_name":"Epigenetics","level":3,"score":0.4448348879814148},{"id":"https://openalex.org/C2781214270","wikidata":"https://www.wikidata.org/wiki/Q4692282","display_name":"Aggressive lymphoma","level":4,"score":0.4166719317436218},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.40487873554229736},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.39477479457855225},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.3944617509841919},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.3352505564689636},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.30214551091194153},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2021-152126","doi":"https://doi.org/10.1182/blood-2021-152126","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-152126","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4310099669","https://openalex.org/W3214226433","https://openalex.org/W4410300601","https://openalex.org/W2600359049","https://openalex.org/W2951735615","https://openalex.org/W2922464087","https://openalex.org/W4389229112","https://openalex.org/W4417012966","https://openalex.org/W7163827968","https://openalex.org/W3137270282"],"abstract_inverted_index":{"Abstract":[0],"KC":[1],"and":[2,18,22,102,148,199,214,251,287,295,321,327,361,387,402,407,416,425,463,490,495,514,579,589,621,643,654,662],"ML":[3],"are":[4,66,105,142,157,524,546,576],"co-first":[5],"authors.":[6],"Background:":[7],"Follicular":[8],"lymphoma":[9,17,207],"(FL)":[10],"is":[11,166,337,352,440,484,660,665],"the":[12,210,246,261,267,277,280,312,434,442,460,480,557,577,586,590,596,614,618],"most":[13],"common":[14],"indolent":[15],"B-cell":[16],"has":[19,75],"a":[20,57,285,319,338,353,393,428,447,455,561,566],"relapsing":[21],"remitting":[23],"course":[24,278],"with":[25,36,50,115,122,170,176,179,224,242,300,356,518,538,628,667],"risk":[26],"of":[27,146,153,197,212,239,257,264,279,290,315,324,375,396,404,411,430,459,468,477,479,492,498,533,543,560,608,611,617,685,696,714,725,737],"transformation":[28,545],"to":[29,39,64,125,190,203,222,248,304,422,446,466,549,555],"aggressive":[30],"disease.":[31,281],"Long-term":[32],"toxicity":[33,52],"can":[34,297],"accumulate":[35],"repeated":[37],"exposure":[38],"palliative":[40],"cytotoxic":[41],"chemotherapy.":[42],"Rationally":[43],"targeted":[44],"agents":[45,310],"have":[46,528],"demonstrated":[47],"disease":[48,638],"control":[49],"limited":[51],"in":[53,69,78,96,150,161,182,260,276,311,329,595,613],"hematologic":[54],"malignancies,":[55],"representing":[56],"potential":[58],"chemotherapy-sparing":[59],"option.":[60],"BCL2":[61,72,103,191,249],"rearrangements":[62,104],"leading":[63],"overexpression":[65],"nearly":[67],"universal":[68],"FL,":[70,116,154],"but":[71,107,155],"inhibition":[73,220,250],"monotherapy":[74],"disappointing":[76],"efficacy":[77,302,322],"FL.":[79,316],"Potential":[80],"reasons":[81],"include":[82,601,632],"known":[83],"resistance":[84,189],"mechanisms,":[85],"such":[86],"as":[87],"MCL-1":[88,183],"overexpression,":[89],"or":[90,305,527,540,687,698,716,727,739],"redundant":[91],"survival":[92],"pathways.":[93],"Founder":[94],"mutations":[95,124],"FL":[97,111,188,201,240,265,332,517,544],"often":[98],"involve":[99],"epigenetic":[100,130,168,237,258],"regulation,":[101],"necessary":[106],"not":[108],"sufficient":[109],"for":[110,270,427,521,585],"lymphomagenesis.":[112,127],"In":[113,206,452],"patients":[114,202,551],"abnormal":[117],"DNA":[118,646],"methylation":[119,647],"programming":[120],"cooperates":[121],"somatic":[123],"drive":[126],"The":[128,254,348,573],"resulting":[129],"deregulation":[131],"may":[132,186,244,273],"be":[133,274,298,371,383,390,419,553],"targetable":[134],"by":[135,593,639],"hypomethylating":[136],"agents,":[137],"including":[138],"azacitadine":[139],"(AZA).":[140],"There":[141],"no":[143],"published":[144],"studies":[145,234],"venetoclax":[147,215,462],"AZA":[149,165,180,193,243],"preclinical":[151,159,233],"models":[152],"there":[156],"extensive":[158],"data":[160],"acute":[162],"myeloid":[163],"leukemia.":[164],"an":[167,475,519,682,693,711,722,734],"modulator":[169],"synergistic":[171],"anti-leukemic":[172],"effect":[173,607],"when":[174],"paired":[175],"venetoclax.":[177],"Treatment":[178],"results":[181],"downregulation,":[184],"which":[185],"abrogate":[187],"inhibition.":[192],"also":[194],"induces":[195],"re-expression":[196],"CD20":[198],"re-sensitizes":[200],"anti-CD20":[204,252,535],"therapy.":[205,253,536],"xenograft":[208],"models,":[209],"combination":[211],"obinutuzumab":[213,296,328,388,426,469],"causes":[216],"more":[217,228],"tumor":[218,641],"growth":[219],"compared":[221],"rituximab":[223],"venetoclax,":[225,291,325],"possibly":[226],"from":[227],"potent":[229],"direct":[230],"cytotoxicity.":[231],"These":[232],"suggest":[235],"that":[236,284],"modulation":[238],"cells":[241],"increase":[245],"sensitivity":[247],"foundational":[255],"position":[256],"dysregulation":[259],"clonal":[262],"evolution":[263],"suggests":[266],"optimal":[268],"time":[269],"this":[271,453,663],"strategy":[272],"early":[275],"We":[282,317],"hypothesize":[283],"safe":[286],"tolerable":[288],"dose":[289,349,359,395,438],"CC-486":[292,380,417,464],"(oral":[293],"AZA),":[294],"found":[299],"treatment":[301,314,522],"equal":[303],"better":[306],"than":[307],"other":[308],"non-chemotherapy":[309],"frontline":[313],"present":[318],"dose-finding":[320,587],"trial":[323,345,650,664],"CC-486,":[326],"minimally":[330],"pre-treated":[331],"patients.":[333],"Study":[334,752],"Design:":[335],"This":[336,649],"single":[339],"arm,":[340],"multi-center":[341],"phase":[342,351,436],"I/II":[343],"clinical":[344,539],"(Figure":[346],"1).":[347],"finding":[350],"3+3":[354],"design":[355,616,651],"3":[357,609],"escalating":[358],"levels":[360,365],"two":[362],"optional":[363],"de-escalation":[364],"(12-18":[366],"patients).":[367],"Venetoclax":[368,415],"(400-800mg)":[369],"will":[370,382,389,418,444,473,552],"given":[372,384,391,420,485],"days":[373,385,399,487],"1-28":[374],"each":[376,412,499],"28":[377],"day":[378,409,496],"cycle;":[379],"(150-200mg)":[381],"1-14;":[386],"at":[392,470,624,656],"fixed":[394],"1000mg":[397],"on":[398,486,582,681,692,710,721,733],"1,":[400,488],"8,":[401,489],"15":[403,491],"cycle":[405,471,493],"1":[406,410,497,671],"then":[408],"subsequent":[413,500],"cycle.":[414,501],"up":[421],"12":[423],"cycles":[424,610],"total":[429],"9":[431],"cycles.":[432],"Once":[433],"recommended":[435],"2":[437],"(RP2D)":[439],"identified,":[441],"study":[443],"proceed":[445],"Simon":[448],"two-stage":[449],"expansion":[450,597,619],"cohort.":[451,598],"cohort,":[454,588,620],"three":[456],"month":[457],"\"window\"":[458],"doublet":[461],"prior":[465],"introduction":[467],"4":[472],"allow":[474],"assessment":[476],"activity":[478],"two-drug":[481],"combination.":[482],"Obinutuzumab":[483],"4,":[494],"Key":[502],"inclusion":[503],"criteria":[504],"are:":[505],"age":[506],"\u2265":[507],"18,":[508],"ECOG":[509],"\u22642;":[510],"adequate":[511],"kidney/liver":[512],"function;":[513],"grade":[515],"1-3a":[516],"indication":[520],"who":[523],"either":[525],"untreated":[526],"\u22642":[529],"courses":[530],"(16":[531],"doses)":[532],"lifetime":[534],"Patients":[537],"histologic":[541],"evidence":[542],"excluded.":[547],"Up":[548],"32":[550],"enrolled":[554],"test":[556],"null":[558],"hypothesis":[559],"30%":[562],"CR":[563,591,622],"rate":[564,592,623],"against":[565],"50%":[567],"alternative":[568],"(80%":[569],"power,":[570],"one-sided":[571],"alpha=0.10).":[572],"primary":[574],"objectives":[575,600,631],"RP2D":[578],"safety":[580],"based":[581],"adverse":[583],"events":[584],"PET":[594],"Secondary":[599],"progression":[602],"free":[603],"survival,":[604,606],"overall":[605],"venetoclax/CC-486":[612],"window":[615],"30":[625],"months":[626],"post-treatment":[627],"PET.":[629],"Exploratory":[630],"pre-treatment":[633],"mutation":[634],"biomarkers,":[635],"minimal":[636],"residual":[637],"circulating":[640,644],"DNA,":[642],"cell-free":[645],"patterns.":[648],"was":[652],"reviewed":[653],"revised":[655],"ASH":[657],"CRTI.":[658],"Recruitment":[659],"ongoing":[661],"registered":[666],"ClinicalTrials.gov:":[668],"NCT04722601.":[669],"Figure":[670,672],"1.":[673],"Disclosures":[674],"Kline:":[675],"Kite/Gilead:":[676],"Speakers":[677],"Bureau;":[678],"Seagen:":[679],"Membership":[680,691,709,720,732],"entity's":[683,694,712,723,735],"Board":[684,695,713,724,736],"Directors":[686,697,715,726,738],"advisory":[688,699,717,728,740],"committees;":[689,700,718,729],"Regeneron:":[690],"Merck:":[701],"Consultancy,":[702,731],"Research":[703,706],"Funding;":[704,707],"Verastem:":[705],"SecuraBio:":[708],"Karyopharm:":[719],"Morphosys:":[730],"committees.":[741],"Smith:":[742],"Celgene,":[743],"Genetech,":[744],"AbbVie:":[745],"Consultancy;":[746],"Alexion,":[747],"AstraZeneca":[748],"Rare":[749],"Disease:":[750],"Other:":[751],"investigator.":[753]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2021-11-22T00:00:00"}